Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.
Cizzle Biotechnology Holdings PLC, a UK-based healthcare diagnostics developer, has announced strategic advancements and an interim financial loss for the first half of 2024. The company raised funds for its commercial lung cancer test, secured partnerships for North American expansion and supply of monoclonal antibodies, and entered a collaboration with Moffitt Cancer Center in Florida. Despite a reported interim loss, these developments signify Cizzle’s transition towards commercialization of their non-invasive CIZ1B biomarker blood test, with a full product launch expected in April 2025.
For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.
